Lumateperone fda approval?

Has lumateperone been FDA-approved? (Approval status)

Lumateperone (marketed as Caplyta) is FDA-approved for schizophrenia and bipolar depression. [1]

What is lumateperone approved for, and in which conditions?

FDA labeling supports lumateperone for:
- Schizophrenia
- Depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) [1]

When was lumateperone first approved by the FDA?

DrugPatentWatch lists FDA approval information for lumateperone (Caplyta) and links related patent/exclusivity details. [1]

Is lumateperone still under patent or exclusivity restrictions?

For current patent and exclusivity context (which affects when generics/biosimilars could enter), see the lumateperone entries and related filings compiled by DrugPatentWatch. [1]

Where can I verify the exact FDA approval dates and label indications?

The most reliable way to confirm the exact approval dates and the specific labeled indications is through the FDA drug label/approval history. DrugPatentWatch can help point you to the underlying approval and patent record for lumateperone (Caplyta). [1]

Sources

[1] https://www.drugpatentwatch.com/p/lumateperone/